Organisation paid for research Program year 2022 Source: CMS Open Payments

RxCrossroads by McKesson

Neither a doctor nor a teaching hospital

Research payments

$70,166,842

70 payments

Through program year 2022, RxCrossroads by McKesson is reported as receiving $70,166,842 in research payments, across 70 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$501,515	2
2021	Research	$27,996,802	30
2020	Research	$35,659,094	34
2019	Research	$6,009,432	4

Breakdown

Who paid Research payments · program years 2019–2022

Pfizer Inc. $55,599,384 62 payments
AstraZeneca Pharmaceuticals LP $14,567,458 8 payments

Studies the money was for Research payments · program years 2019–2022

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed Highrisk Ball Risk Adapted Postinduction Therapy for Highrisk Ball Mixed Phenotype Acute Leukemia and Disseminated Blly $27,613,916 16 payments
Wi208323 Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin A Conjugated Anticd22 Monoclonal Antibody to Frontline Therapy in Young Adults Ages 1639 Years With Newly Diagnosed Precursor Bcell All $7,450,472 10 payments
Combination of Mek Inhibitor Binimetinib and Cdk46 Inhibitor Palbociclib in Kras and Nras Mutant Metastatic Colorectal Cancers $7,381,426 16 payments
Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin A Conjugated Anticd22 Monoclonal Antibody to Frontline Therapy in Young Adults Ages 1639 Years With Newly Diagnosed Precursor Bcell All $6,943,591 7 payments
A Phase II study of acalabrutinib, venetoclax, and obinutuzumab AVO for initial therapy of CLL $4,219,200 1 payment
A randomized phase 2 study comparing acalabrutinib to acalabrutinib and obinutuzumab in the treatment of patients with early-stage CLL/SLL who are at high risk of disease progression. $3,459,744 1 payment
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults With Relapsed Or Refractory Cd22 Bacute Lymphoblastic Leukemia Ballwi250421 $2,899,643 3 payments
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patietns with Germline or Somatic Mutations in DNA Repair Genes $1,841,525 1 payment
A Phase II study of Olaparib in patients with advanced biliary tract cancer expressing aberrant DNA repair $1,784,903 1 payment
A phase II study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic and Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair $1,759,200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.